Biotech News
PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
– Positive FREEDOM2-DM1 10 mg/kg cohort results demonstrated highest reported splicing correction and improvements across multiple functional measures – – 12.5 mg/kg FREEDOM2-DM1 cohort fully enrolled, with participants having received up to three doses; results expected in 1H 2027 – – FREEDOM-OLE
